LinkinVAX Unveils "PanCov," a Novel Multi-variant Vaccine to Combat Covid and Other Coronaviruses, Completing First Batch Production
PARIS & TOULOUSE, France, July 20, 2023 (VSNewsNetwork.com) - LinkinVax, a clinical-stage biotech firm, has declared the successful manufacturing and bottling of a GMP batch of its revolutionary pan-sarbecovirus vaccines, PanCov, which is designed to prevent COVID-19 and other known coronavirus diseases.
This innovative protein-based vaccine is unique as it targets sequences of SARS-CoV-2 and its variants, in addition to sequences common to other coronaviruses, thereby aiming to elicit broad and enduring immune responses.
Falling within the WHO’s booster vaccination strategy, PanCov aims to forestall a resurgence of the pandemic and its health and economic impacts globally. Compliant with the requirements of the NextGen program defined by the US, the vaccine is multi-variant, long-lasting, and both easy and cost-effective to manufacture and store.
“Our ambition is to create a robust and enduring vaccine with a booster effect, effective against various SARS-CoV-2 variants, as well as other coronaviruses to prevent the emergence of new pandemics," stated André-Jacques Auberton-Hervé, President and Co-Founder of LinkinVax. He emphasized the company's strategy to leverage the latest artificial intelligence (AI) tools to accelerate the production of effective vaccine solutions in the event of a pandemic.
The collaboration between LinkinVax, French GTP Bioways, and European FAREVA, which began in March 2022, culminated in the timely and efficient production of the first GMP batch of the PanCov vaccine. This joint effort underscores the French industry's ability to provide solutions to global health needs.
"We are proud of our contribution to the production of this next-generation COVID-19 vaccine," expressed Alexandre Bastit, CEO of Business Unit Pharma and API at FAREVA, underscoring the industry's prowess in developing and producing innovative healthcare products.
Following compliance validation and toxicology results, the release of the PanCov GMP batch is anticipated in Q3 2023, with clinical trials slated to commence early 2024.
The vaccine, designed in France by the Vaccine Research Institute (VRI/INSERM/UPEC) and developed by LinkinVax, is supported by Bpifrance as part of the PSPC Evidence Project and the French Investing for the Future Programme (PIA).
Visit www.linkinvax.com to learn more about LinkinVax and its technology.
Source: LinkinVax via Business Wire
